Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2015

View Archived Issues

Servier discloses novel Bcl-2 antagonists

Teijin Pharma reports development of novel xanthine oxidase inhibitors

Janssen discloses FLAP inhibitors

Bayer discloses BRD4 inhibitors

Takeda presents OX1 receptor antagonists

Bristol-Myers Squibb patents HIV integrase inhibitors

Lundbeck divulges BACE1 inhibitors

Neurons in Alzheimer's brains respond to nerve growth factor

Incyte discloses LSD1 inhibitors

Bayer expands finerenone program with three phase III studies

Ono Pharmaceuticals presents novel autotaxin inhibitors

Bionomics to begin phase I trial of BNC-101

Seikagaku terminates license agreement with Can-Fite BioPharma for RA product

Hisamitsu Pharmaceutical begins phase II study of HP-3150 in Japan

Eisai and Purdue to codevelop insomnia candidate lemborexant

ALK's house dust mite allergy immunotherapy approved in 11 European countries

Kanuma becomes first approved treatment in E.U. for LAL-D

FDA grants priority review to Intercept's NDA for obeticholic acid for primary biliary cirrhosis

Probuphine NDA resubmitted to FDA

First oral agent for Gaucher's disease launched in Japan

Initial results reported from phase I trial of RNAi therapeutic ALN-PCSsc

Dabrafenib-trametinib combination approved in the E.U. for BRAF V600 mutation-positive melanoma

Bristol-Myers Squibb gains exclusive right to acquire Promedior

Valeant licenses rights to brodalumab from AstraZeneca

European approval of Strensiq for pediatric-onset hypophosphatasia

Lipocine files U.S. NDA for testosterone replacement therapy LPCN-1021

Asahi Kasei announces launch date for Xiaflex in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...